Status:

COMPLETED

The Dose of Sugammadex for Rapid Reversal of Profound Neuromuscular Block in Young and Elderly Patients

Lead Sponsor:

Severance Hospital

Conditions:

Anesthesia Recovery Period, Neuromuscular Blockade

Eligibility:

All Genders

20+ years

Phase:

NA

Brief Summary

To find out the dose of sugammadex for recovery of the TOF ratio to 0.9 within 2 minutes from profound rocuronium-induced neuromuscular block in young and elderly adult patients.

Detailed Description

A previous study reported that elderly patients required a longer time to recover from rocuronium induced neuromuscular block compared to younger patients. Therefore, the aim of this study is to find ...

Eligibility Criteria

Inclusion

  • 20-40 years or ≥70 years ASA class I-II patients who received surgery less than 2 hours.

Exclusion

  • anticipated difficult intubation
  • neuromuscular, hepatic or renal disorders
  • drug allergy
  • body mass index \>30 kg/m2 or body mass index \<18 kg/m2
  • emergency surgery

Key Trial Info

Start Date :

June 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2014

Estimated Enrollment :

44 Patients enrolled

Trial Details

Trial ID

NCT01890057

Start Date

June 1 2013

End Date

January 1 2014

Last Update

February 4 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Anesthesiology and Pain Medicine and Anesthesia and Pain Research Institute, Yonsei University College of Medicine

Seoul, South Korea